A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

被引：5
|
作者：
Yee, Andrew Jenho
Laubach, Jacob
Campagnaro, Erica Leigh
Lipe, Brea
Nadeem, Omar
Cole, Craig
O'Donnell, Elizabeth
Schlossman, Robert L.
Bianchi, Giada
Branagan, Andrew Robert
Shapiro, Samantha J.
Harrington, Cynthia C.
Burke, Jill N.
Gammon, Marilyn T.
Lively, Kathleen J.
Thorburn, Cassandra Ann
Mann, Mason L.
Lohr, Jens Guenter
Richardson, Paul G.
Raje, Noopur S.
机构：
[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA
[4] Univ Rochester, Rochester, NY USA
[5] Newton Wellesley Hosp, Newton, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8012
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra A.
    Mann, Mason L.
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    [J]. BLOOD, 2019, 134
  • [2] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
    San Miguel, Jesus
    Raab, Marc S.
    Goldschmidt, Hartmut
    Lonial, Sagar
    Richardson, Paul G.
    Shelat, Suresh
    Bleickardt, Eric W.
    Palumbo, Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.
    Gasparetto, Cristina
    Green, Michael
    Srinivasan, Anandgopal
    Kang, Yubin
    Rizzieri, David A.
    Decastro, Carlos
    Diehl, Louis F.
    Beaven, Anne
    Li, Zighuo
    Rao, Arati V.
    Garrett, Anderson
    Tuchman, Sascha
    Long, Gwynn D.
    [J]. BLOOD, 2015, 126 (23)
  • [4] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Gasparetto, Cristina
    Bowles, Kristian M.
    Abdallah, Al-Ola
    Morris, Lura
    Mander, Gudrun
    Coppola, Sheryl
    Wang, Jing
    Ross, Jeremy A.
    Bueno, Orlando F.
    Arriola, Emma
    Mateos, Maria Victoria
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 775 - 784
  • [5] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Phase lb study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.
    Laubach, Jacob
    Tuchman, Sascha Alexander
    Rosenblatt, Jacalyn
    Redd, Robert
    Colson, Kathleen
    Motta, Ashley
    Fitzpatrick, Kathleen
    Weller, Edie
    Richardson, Paul G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.
    Alsina, Melissa
    Schlossman, Robert L.
    Weber, Donna M.
    Coutre, Steven E.
    Lonial, Sagar
    Gasparetto, Cristina
    Warsi, Ghulam
    Ondovik, Michael S.
    Mukhopadhyay, Sutapa
    Paley, Carole S.
    Richardson, Paul Gerard Guy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
    Kropff, MH
    Bisping, G
    Wenning, D
    Berdel, WE
    Kienast, J
    [J]. BLOOD, 2004, 104 (11) : 313B - 313B
  • [10] Elotuzumab in Combination with Pomalidomide and Corticosteroids for Relapsed or Refractory Multiple Myeloma
    Sidiqi, Hasib
    McGregor, Scott
    Baker, Ross
    Carnley, Ben
    Radeski, Dejan
    Barraclough, Allison
    Augustson, Bradley
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E83 - E84
12345